JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognosis of Patients with Hepatocellular Carcinoma Treated with TACE: A New Score Combining Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin

  • 0Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Journal of Hepatocellular Carcinoma +

|

October 28, 2024

|

October 28, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A new AD score using alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) offers superior prediction for hepatocellular carcinoma (HCC) patients undergoing TACE. This prognostic tool improves risk assessment and survival prediction.

Area Of Science

  • Hepatology
  • Oncology
  • Biomarkers

Background

  • Hepatocellular carcinoma (HCC) poses a global health challenge, necessitating accurate prognostic tools for treatment planning.
  • Transarterial chemoembolization (TACE) is a common treatment for HCC, requiring effective preoperative risk assessment.

Purpose Of The Study

  • To develop and validate the AD score, a novel risk prediction tool for HCC.
  • To assess the preoperative prognostic accuracy of the AD score using serum alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) levels.
  • To compare the AD score's performance against existing prognostic models in HCC patients undergoing TACE.

Main Methods

  • Retrospective analysis of 295 HCC patients undergoing TACE, divided into training (n=147) and testing (n=148) sets.
  • Construction of the AD score using log-transformed serum AFP and DCP levels.
  • Validation using multivariate Cox regression and comparison with established models (Child Pugh, BCLC, ALBI, etc.) via time-dependent ROC curves and risk stratification.

Main Results

  • The AD score demonstrated superior predictive accuracy for HCC prognosis compared to existing models.
  • Time-dependent ROC analysis confirmed the AD score's consistent superiority over a 5-year period.
  • Risk stratification using the AD score into low, intermediate, and high groups showed significant survival differences in both training and testing cohorts.

Conclusions

  • The AD score provides an objective and simple prognostic tool for HCC patients undergoing TACE.
  • The AD score enhances predictive accuracy and clinical utility for preoperative risk assessment.
  • The AD score represents a potentially significant addition to the preoperative assessment of HCC patients undergoing TACE.

Keywords: